Exact Sciences Stock Could Sprint Higher in the Weeks Ahead
EXAS is likely to consolidate its recent gains.
Opko Health Successfully Tests a Bottom and Is Ready to Rise
A correction in the shares of the provider of Covid-19 tests appears to be over and a new uptrend is underway.
GoodRx Hasn't Been Public Long But Here's What We Know
GDRX will not stay in a tight range for long.
Jim Cramer: The President's Behavior Towards Covid-19
I know that Trump's going to blunt our community mask initiative because who needs masks if it isn't a big deal if you are sick?
Does 'Aggressive' Bristol-Myers Have the Right Prescription for Investors?
BMY's announced acquisition of MyoKardia for $13B comes less than a year after its purchase of Celgene.
Jim Cramer: Covid-19, the Aerosol Factor, and Why We Wear Masks
An unyielding disdain for scientists permeates this administration. But if you listen to these professors the nation wouldn't be in this fix.
The Economic Recovery Moves Sideways
What does it all mean?
Seattle Genetics Hits New Highs and a Strategy Adjustment Is Needed
The charts and indicators of SGEN are looking healthy.
Jim Cramer: You Heard the Ugly of the Debate. Here's the Good.
Neither candidate seems to be the enemy of the market -- at least not yet.
Bearish Bets: 2 Healthcare Stocks You Should Consider Shorting This Week
These names are displaying both technical and quantitative deterioration.